HomeAI · summaries
Storia in 5 fonti
Jury Hits Takeda With $885 Million Antitrust Verdict - Takeda Pharmaceutical Co (NYSE:TAK)
Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions and appeal.
Confronto fonti
5 prospettive sulla stessa storiaTimeline cronologica
- ·
asia.nikkei.com
Takeda found liable over antitrust plot to delay generic constipation drug
Japanese drugmaker was accused by US pharmacies, retailers of 'pay-for-delay' scheme
- ·
morningstar.com
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
- ·
fiercepharma.com
Takeda slapped with $885M verdict in pay-for-delay antitrust case
Takeda plans to appeal after a federal jury found it liable in a landmark pay-for-delay antitrust case and ordered the Japanese drugmaker to pay $885 million in damages, a figure…
- ·
benzinga.com
Jury Hits Takeda With $885 Million Antitrust Verdict - Takeda Pharmaceutical Co (NYSE:TAK)
Takeda faces nearly $885 million jury verdict in AMITIZA antitrust case and plans post-trial motions and appeal.
- ·
pharmaceutical-technology.com
Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict - Pharmaceutical Technology
Takeda confirmed it would appeal the outcome, stating that the case “lacks merit”.